The Three Control Failures Turning Hospital AI Audit Readiness Into an Active Liability

The Readiness Gap Is Not a Maturity Problem

The question regulators will eventually ask every health system is not whether their AI works. It is whether the health system can prove, on demand, that the AI worked appropriately, that clinicians retained meaningful control, and that any adverse outcome can be traced to an accountable decision point. Industry estimates, including assessments from healthcare AI governance practitioners and early audit findings circulated in policy forums, consistently suggest that fewer than one in four hospitals could satisfy that demand today. That is not a maturity gap. It is an active regulatory liability, and the FDA, CMS, and HIPAA enforcement cycles now converging on AI-enabled clinical systems will make it visible.

This article does not rehearse the general case for AI governance. Senior compliance and risk leaders in health systems already accept the principle. What they need is a precise diagnosis of where the control structure breaks, and a concrete starting point for remediation. Three failures account for most of the exposure: the absence of a centralized AI model inventory, the failure to capture human-override events, and the absence of any explainability pipeline. Each failure is remediable. None of them require a multi-year program to address at a basic level.

Control Failure One: No Centralized AI Inventory

The most foundational hospital AI audit readiness failure is also the most avoidable. A health system cannot govern, explain, or audit a model it has not registered. Yet across mid-to-large health systems, AI and algorithmic tools have been acquired through multiple pathways — embedded in EHR platforms, procured as point solutions by individual service lines, built by internal data science teams, and inherited through acquisitions. The result is a distributed, informally documented population of live clinical decision-support tools with no single owner and no unified record.

NIST's AI Risk Management Framework, specifically the GOVERN function, requires organizations to establish accountability and documentation for AI systems commensurate with their risk. ISO 42001, the international standard for AI management systems, makes a similar demand in its clause 6 planning controls: you must know what AI you have, where it is used, what decisions it influences, and who is accountable for it. Neither standard is satisfied by a spreadsheet maintained by one team member. A credible inventory requires defined ownership, a classification of each system's risk tier, documentation of the data the model was trained on, and a refresh cadence. Most health systems do not have this. Starting the remediation means designating an accountable owner, running a deliberate discovery exercise across procurement, IT, and clinical informatics records, and building the registry in a format that can be produced to a regulator in days, not weeks.

Control Failure Two: Human-Override Events Are Not Being Captured

Clinicians override AI recommendations constantly. A radiologist flags a scan the AI cleared. An ED physician orders a different treatment than the risk-stratification tool suggested. A pharmacist substitutes a drug the prescribing-support system did not recommend. These events are clinically routine and operationally invisible. Almost no health system has a structured mechanism for logging them, attributing them to a specific AI system, and aggregating them for post-market review.

This is not a theoretical gap. The FDA's evolving guidance on AI-enabled medical devices — particularly the 2021 Action Plan for AI/ML-based Software as a Medical Device and subsequent discussion papers — explicitly anticipates continuous learning and post-market performance monitoring as core obligations. CMS quality reporting frameworks increasingly reference algorithm-assisted decisions in the context of care appropriateness reviews. If a health system cannot demonstrate that its clinicians retained and exercised meaningful control over AI-assisted decisions, it cannot demonstrate that the system operated within its intended use envelope. Override capture does not require a new platform. It requires a deliberate instrumentation decision: define what constitutes a material override, build or configure logging into the existing clinical workflow, establish a review cadence, and assign a responsible reviewer. The tooling category here is post-market surveillance and model monitoring; vendors in this space include both EHR-native analytics and standalone model observability platforms. The effort to instrument a single high-risk system is measured in weeks, not quarters.

Control Failure Three: No Explainability Pipeline

The third failure is the most technically complex and the most frequently deferred. An explainability pipeline is the operational infrastructure that allows a health system to generate, on demand, a plain-language account of why a specific AI system produced a specific output for a specific patient at a specific time. It is distinct from model interpretability at training time. A model can be globally interpretable and still produce no auditable explanation for a specific inference.

The EU AI Act classifies AI systems used in clinical decision support as high-risk under Annex III and requires that providers be able to explain the system's outputs to both regulators and affected individuals. While the EU AI Act applies directly to European health systems and to vendors selling into the EU, its influence on FDA guidance and on HIPAA's algorithmic accountability expectations is already observable in regulatory commentary. HIPAA's proposed privacy rule updates have referenced algorithmic decision-making in the context of individual rights. For a CRO or CCO, the practical question is not whether explainability will be required — it will — but whether the infrastructure to produce it is being built now or will be scrambled together under enforcement pressure. The remediation path begins with identifying which models in the inventory produce decisions that could be subject to patient or regulator challenge, selecting an explanation method appropriate to each model type (SHAP values for tree-based models, attention attribution for transformer-based systems, rule extraction for simpler classifiers), and building a logging and retrieval layer that makes those explanations accessible outside the data science environment.

A Self-Assessment Starting Point

Before commissioning a full audit program, a health system's compliance leadership can apply a five-question diagnostic. First: does a single, owned document list every AI or algorithmic system in clinical use, with a named accountable individual for each? Second: is there a defined process for logging and reviewing clinician overrides of AI recommendations, and has it been tested in the last ninety days? Third: can the team produce a plain-language explanation for why a specific AI recommendation was made for a specific patient within forty-eight hours of a request? Fourth: has each AI system been classified against a risk tier framework — NIST AI RMF or ISO 42001 are the natural references — and has that classification been reviewed since the system's last significant update? Fifth: is there a documented process for retiring or revalidating a model when its input data distribution shifts materially?

A 'no' answer to any of these questions is a control gap. Two or more 'no' answers in the first three questions represents material audit exposure under any plausible FDA, CMS, or HIPAA enforcement scenario. This is not a comprehensive audit checklist. It is the threshold test that determines whether a health system is operating in a defensible posture or in a posture of unacknowledged liability.

Assurance Is Not a Future-State Project

The health systems that will navigate the incoming enforcement cycle without material findings are not the ones with the most sophisticated AI. They are the ones that treated the control infrastructure — inventory, override capture, explainability — as a present obligation rather than a roadmap item. Audit failure is not a future risk that might arrive with the next regulation. For most health systems, it is a present-tense condition waiting to be exposed. The remediation path is known, the frameworks exist, and the window to act before enforcement arrives is narrowing. Building hospital AI audit readiness now, anchored to NIST AI RMF and ISO 42001 controls, is the most defensible posture available.